| Metric | Value ($ M) | Q1 FY25 |
|---|---|---|
| Revenue | 207.71 | 38.6% |
| Total Income | 207.71 | 38.6% |
| Expenditure | 216.04 | 35.0% |
| PBT | -5.95 | 2.1% |
| Net Profit | -2.29 | 80.6% |
| OPM | -4.01% | 2.83pp |
| NPM | -1.10% | 6.79pp |
| EPS | -0.04 | 81.0% |
Supernus Reports Q1 2026 Revenue Up 39% YoY
06 May 2026 · 6 May, 1:45 am
Summary
Supernus Pharmaceuticals, Inc. announced financial results for the first quarter 2026, with total revenues of $207.7 million, a 39% increase compared to the same period last year. The combined revenues of the company's four growth products increased by 56% to $149.1 million. The company recognized $20.0 million of licensing revenue related to the achievement of a commercial milestone under its collaboration agreement with Shionogi. The Company reiterates full year 2026 financial guidance.
Key Highlights
- 1
Total revenues were $207.7 million in the first quarter 2026, a 39% increase compared to the same period last year.
- 2
Combined revenues of the Company's four growth products increased to $149.1 million in the first quarter 2026, representing an increase of 56% compared to the same period last year.
- 3
ONAPGO net product sales were $8.4 million in the first quarter of 2026, reflecting resumption of new patient initiation in February 2026.
- 4
Collaboration revenue from ZURZUVAE was $27.6 million in the first quarter of 2026.
- 5
Net sales of Qelbree increased 20% to $77.9 million in the first quarter of 2026, compared to the same period in 2025.
- 6
Net sales of GOCOVRI increased 15% to $35.2 million in the first quarter of 2026, compared to the same period in 2025.
- 7
The Company reiterates full year 2026 financial guidance.
Management Comments
Jack Khattar
“Our first quarter results reflect a strong start to the year, including a 56% year-over-year increase in combined revenues of our growth products. We have positive momentum across our business, and I look forward to continued strong growth and execution of our key products throughout the year.”
Informational and educational content only. Not investment advice.